Cerebral Small Vessel Diseases
Conditions
Brief summary
The aim of this study is to determine the clinical spectrum and natural progression of Cerebral Small Vessel Disease (CSVD) and in a prospective multicenter study, to assess the clinical, genetic and epigenetic features of patients with CSVD, , to find independent imaging markers, and to optimize clinical management.
Interventions
None listed
Sponsors
Bin Cai
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Sign informed consent. 2. Age\>18 3. At least one of the following CSVD MRI characteristics: ①recent small subcortical infarct;②lacune of presumed vascular origin;③white matter hypertensity of presumed vascular origin;④perivascular space;⑤cerebral microbleeds;⑥brain atrophy
Exclusion criteria
1. Unable to cooperate with inspectors 2. Non-vascular white matter lesions 3. Other cognitive diseases (such as alzheimer's disease, Parkinson's disease or thyroid disease) 4. Serious systemic illness, such as heart, liver, kidney disease or major mental illness 5. Contraindications for imaging examination
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall outcomes in patients with cerebral small vessel disease. | From date of enrollment until the date of death from any cause, assessed up to 30 years | record the occurrence of stroke and use modified Rankin Scale (mRS) to measure the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the development of lacunes in MRI | From date of enrollment until the date of death from any cause, assessed up to 30 years | record the number and location of lacunes |
| the development of the burden of microbleeds in MRI | From date of enrollment until the date of death from any cause, assessed up to 30 years | using MARS scale to evaluate the development of the burden of microbleeds |
| the development of the burden of white matter hypertension in MRI | From date of enrollment until the date of death from any cause, assessed up to 30 years | using Fazakes scale to evaluate the development of the burden of white matter hypertension |
| the development of enlarged perivascular space in MRI | From date of enrollment until the date of death from any cause, assessed up to 30 years | record the number and location of enlarged perivascular space |
Countries
China
Contacts
Primary ContactBin Cai, PhD
Outcome results
None listed